HitGen Inc
SSE:688222

Watchlist Manager
HitGen Inc Logo
HitGen Inc
SSE:688222
Watchlist
Price: 13.22 CNY 1.23%
Market Cap: 5.3B CNY
Have any thoughts about
HitGen Inc?
Write Note

HitGen Inc
Investor Relations

HitGen, Inc. engages in the provision deoxyribonucleic acid encoded compound library (DEL) for research and development of seed and lead compounds. The company is headquartered in Chengdu, Sichuan and currently employs 508 full-time employees. The company went IPO on 2020-04-16. The firm focuses on the research and creation of deoxyribonucleic acid encoded compound library (DEL) technology, research and development of hit compounds and lead compounds. The firm mainly provides DEL screening services, DEL library customization services, chemical synthesis services and transfer of new drug research and development projects. The firm conducts its businesses within the domestic market and to overseas markets.

Show more

Earnings Calls

No Earnings Calls Available

Management

Mr. Li Jin
Chairman & GM
No Bio Available
Dr. Hongge Liu CFA, Ph.D.
Chief Financial Officer
No Bio Available
Ms. Chunyan Hu
Accounting Supervisor
No Bio Available
Mr. Shiwei Geng
Secretary
No Bio Available
Mr. Barry A. Morgan
Chief Scientist
No Bio Available

Contacts

Address
SICHUAN
Chengdu
Chengdu Tianfu International Biological City (Building 6, No. 8, Huigu East 1st Road, Shuangliu District)
Contacts
+862885197385
www.hitgen.com